Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

Breast cancer; Predictive markers

Detalles Bibliográficos
Autores: Chumsri, Saranya, Li, Zhuo, Serie, Daniel J., Norton, Nadine, Mashadi-Hossein, Afshin, Tenner, Kathleen, Saura Manich, Cristina
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Departament de Salut de la Generalitat de Catalunya (DS)
Repositorio:Scientia. Dipòsit d'Informació Digital del Departament de Salut
OAI Identifier:oai:scientiasalut.gencat.cat:11351/8055
Acceso en línea:https://hdl.handle.net/11351/8055
Access Level:acceso abierto
Palabra clave:Mama - Càncer - Tractament
Expressió gènica
Resposta immunitària
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
PHENOMENA AND PROCESSES::Genetic Phenomena::Gene Expression Regulation::Gene Expression Regulation, Neoplastic
PHENOMENA AND PROCESSES::Immune System Phenomena::Dose-Response Relationship, Immunologic
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
FENÓMENOS Y PROCESOS::fenómenos genéticos::regulación de la expresión génica::regulación de la expresión génica neoplásica
FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::relación dosis-respuesta inmunológica
id ES_b4bf0c9643f2ef0f161e89c3bf1be666
oai_identifier_str oai:scientiasalut.gencat.cat:11351/8055
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
title Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
spellingShingle Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
Chumsri, Saranya
Mama - Càncer - Tractament
Expressió gènica
Resposta immunitària
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
PHENOMENA AND PROCESSES::Genetic Phenomena::Gene Expression Regulation::Gene Expression Regulation, Neoplastic
PHENOMENA AND PROCESSES::Immune System Phenomena::Dose-Response Relationship, Immunologic
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
FENÓMENOS Y PROCESOS::fenómenos genéticos::regulación de la expresión génica::regulación de la expresión génica neoplásica
FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::relación dosis-respuesta inmunológica
title_short Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
title_full Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
title_fullStr Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
title_full_unstemmed Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
title_sort Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
dc.creator.none.fl_str_mv Chumsri, Saranya
Li, Zhuo
Serie, Daniel J.
Norton, Nadine
Mashadi-Hossein, Afshin
Tenner, Kathleen
Saura Manich, Cristina
author Chumsri, Saranya
author_facet Chumsri, Saranya
Li, Zhuo
Serie, Daniel J.
Norton, Nadine
Mashadi-Hossein, Afshin
Tenner, Kathleen
Saura Manich, Cristina
author_role author
author2 Li, Zhuo
Serie, Daniel J.
Norton, Nadine
Mashadi-Hossein, Afshin
Tenner, Kathleen
Saura Manich, Cristina
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Chumsri S] Jacoby Center for Breast Health, Mayo Clinic, Jacksonville, FL, USA. [Li Z, Serie DJ] Department of Health and Human Services, Mayo Clinic, Jacksonville, FL, USA. [Norton N] Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA. [Mashadi-Hossein A] NanoString, Inc., Seattle, WA, USA. [Tenner K] Department of Health and Human Services, Mayo Clinic, Rochester, MN, USA. [Saura C] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Mama - Càncer - Tractament
Expressió gènica
Resposta immunitària
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
PHENOMENA AND PROCESSES::Genetic Phenomena::Gene Expression Regulation::Gene Expression Regulation, Neoplastic
PHENOMENA AND PROCESSES::Immune System Phenomena::Dose-Response Relationship, Immunologic
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
FENÓMENOS Y PROCESOS::fenómenos genéticos::regulación de la expresión génica::regulación de la expresión génica neoplásica
FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::relación dosis-respuesta inmunológica
topic Mama - Càncer - Tractament
Expressió gènica
Resposta immunitària
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
PHENOMENA AND PROCESSES::Genetic Phenomena::Gene Expression Regulation::Gene Expression Regulation, Neoplastic
PHENOMENA AND PROCESSES::Immune System Phenomena::Dose-Response Relationship, Immunologic
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
FENÓMENOS Y PROCESOS::fenómenos genéticos::regulación de la expresión génica::regulación de la expresión génica neoplásica
FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::relación dosis-respuesta inmunológica
description Breast cancer; Predictive markers
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/8055
url https://hdl.handle.net/11351/8055
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv NPJ Breast Cancer;8
https://doi.org/10.1038/s41523-022-00430-0
dc.rights.none.fl_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Nature Research
publisher.none.fl_str_mv Nature Research
dc.source.none.fl_str_mv Scientia
reponame:Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname:Departament de Salut de la Generalitat de Catalunya (DS)
instname_str Departament de Salut de la Generalitat de Catalunya (DS)
reponame_str Scientia. Dipòsit d'Informació Digital del Departament de Salut
collection Scientia. Dipòsit d'Informació Digital del Departament de Salut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417286505332736
spelling Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trialsChumsri, SaranyaLi, ZhuoSerie, Daniel J.Norton, NadineMashadi-Hossein, AfshinTenner, KathleenSaura Manich, CristinaMama - Càncer - TractamentExpressió gènicaResposta immunitàriaDISEASES::Neoplasms::Neoplasms by Site::Breast NeoplasmsOther subheadings::Other subheadings::Other subheadings::/drug therapyPHENOMENA AND PROCESSES::Genetic Phenomena::Gene Expression Regulation::Gene Expression Regulation, NeoplasticPHENOMENA AND PROCESSES::Immune System Phenomena::Dose-Response Relationship, ImmunologicENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mamaOtros calificadores::Otros calificadores::Otros calificadores::/farmacoterapiaFENÓMENOS Y PROCESOS::fenómenos genéticos::regulación de la expresión génica::regulación de la expresión génica neoplásicaFENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::relación dosis-respuesta inmunológicaBreast cancer; Predictive markersCáncer de mama; Marcadores predictivosCàncer de mama; Marcadors predictiusTrastuzumab acts in part through the adaptive immune system. Previous studies showed that enrichment of immune-related gene expression was associated with improved outcomes in HER2-positive (HER2+) breast cancer. However, the role of the immune system in response to lapatinib is not fully understood. Gene expression analysis was performed in 1,268 samples from the North Central Cancer Treatment Group (NCCTG) N9831 and 244 samples from the NeoALTTO trial. In N9831, enrichment of CD45 and immune-subset signatures were significantly associated with improved outcomes. We identified a novel 17-gene adaptive immune signature (AIS), which was found to be significantly associated with improved RFS among patients who received adjuvant trastuzumab (HR 0.66, 95% CI 0.49–0.90, Cox regression model p = 0.01) but not in patients who received chemotherapy alone (HR 0.96, 95% CI 0.67–1.40, Cox regression model p = 0.97). This result was validated in NeoALTTO. Overall, AIS-low patients had a significantly lower pathologic complete response (pCR) rate compared with AIS-high patients (χ2 p < 0.0001). Among patients who received trastuzumab alone, pCR was observed in 41.7% of AIS-high patients compared with 9.8% in AIS-low patients (OR of 6.61, 95% CI 2.09–25.59, logistic regression model p = 0.003). More importantly, AIS-low patients had a higher pCR rate with an addition of lapatinib (51.1% vs. 9.8%, OR 9.65, 95% CI 3.24–36.09, logistic regression model p < 0.001). AIS-low patients had poor outcomes, despite receiving adjuvant trastuzumab. However, these patients appear to benefit from an addition of lapatinib. Further studies are needed to validate the significance of this signature to identify patients who are more likely to benefit from dual anti-HER2 therapy. ClinicalTrials.gov Identifiers: NCT00005970 (NCCTG N9831) and NCT00553358 (NeoALTTO).Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180882 and U24CA196171 (to the Alliance for Clinical Trials in Oncology); UG1CA233180, UG1CA232760, UG1CA233373, and U10CA180821. https://acknowledgments.alliancefound.org. Also supported in part by funds from the Department of Defense W81XWH-18-1-0562 and −0563 and W81XWH-16-1-0265 and 0266, as well as the Breast Cancer Research Foundation (BCRF-19-161), Bankhead-Coley Research Program (6BC05), Susan G. Komen Foundation (SAC190091), and the DONNA Foundation. The content is solely the authors’ responsibility and does not necessarily represent the official views of the National Institutes of Health. Genentech/Roche supplied trastuzumab for both trials. Presented at the Spotlight Session at San Antonio Breast Cancer Symposium 2016 and the ASCO Annual Meeting 2018. Portions of this paper have been published in abstract form: Journal of Clinical Oncology 36, no. 15_suppl (May 20, 2018) 577.Nature ResearchInstitut Català de la Salut[Chumsri S] Jacoby Center for Breast Health, Mayo Clinic, Jacksonville, FL, USA. [Li Z, Serie DJ] Department of Health and Human Services, Mayo Clinic, Jacksonville, FL, USA. [Norton N] Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA. [Mashadi-Hossein A] NanoString, Inc., Seattle, WA, USA. [Tenner K] Department of Health and Human Services, Mayo Clinic, Rochester, MN, USA. [Saura C] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, SpainVall d'Hebron Barcelona Hospital Campus202220222022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/8055Scientiareponame:Scientia. Dipòsit d'Informació Digital del Departament de Salutinstname:Departament de Salut de la Generalitat de Catalunya (DS)InglésNPJ Breast Cancer;8https://doi.org/10.1038/s41523-022-00430-0Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:scientiasalut.gencat.cat:11351/80552026-06-12T09:38:37Z
score 15,811543

Similares en LA Referencia